Obesity | Jotup

Global Interactive Wound Dressing Market Report 2023: Sector is Expected to Reach $5.9 Billion by 2030 at a CAGR of 4.6% - ResearchAndMarkets.com

Retrieved on:

Wednesday, May 31, 2023

Pharmaceutical, Health, Medical Supplies, COVID-19, Growth, Burns, Obesity, WHO, Prevalence, Patient, Wound healing, Nursing, Video game

Advancements in technology have led to the development of wound dressings that can monitor the healing process and provide real-time feedback to healthcare professionals.

Key Points:

Advancements in technology have led to the development of wound dressings that can monitor the healing process and provide real-time feedback to healthcare professionals.
This has increased the demand for interactive wound dressings that can provide real-time feedback and help healthcare professionals remotely monitor wound healing.
In 2022, based on the application chronic wound segment dominated the market in terms of the revenue share of 59.8%.
The acute wound segment is expected to witness the fastest CAGR of 4.7% over the forecast period.

Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity

Retrieved on:

Wednesday, May 31, 2023

T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.

Key Points:

T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.
“Type 2 diabetes and obesity are extremely common chronic diseases where the outcome of most therapeutic options is suboptimal.
“These Phase 2a data provide clinical evidence that duodenal exclusion may be possible with a non-invasive, orally administered, pharmaceutical treatment.
He will discuss therapeutic targets in the gut for the treatment of T2D and obesity.

Global Companion Animal Rehabilitation Services Market Report 2023: Sector is Expected to Reach $1.18 Billion by 2030 at a CAGR of 11.42% - ResearchAndMarkets.com

Retrieved on:

Tuesday, May 30, 2023

The global companion animal rehabilitation services market size is expected to reach USD 1.18 Billion by 2030 to expand at a CAGR of 11.42% from 2023 to 2030.

Key Points:

The global companion animal rehabilitation services market size is expected to reach USD 1.18 Billion by 2030 to expand at a CAGR of 11.42% from 2023 to 2030.
The major goal of physical rehabilitation in pet cats and dogs is to speed healing, decrease pain or discomfort, and improve their well-being.
Dogs and horses involved in sporting activities are widely known to be benefited from rehabilitation services with high patient compliance.
North America is expected to dominate the companion animal rehabilitation services market throughout the projected period owing to the region's large pet care expenditure and pet population.

Allurion to Participate in the Jefferies Healthcare Conference

Retrieved on:

Tuesday, May 30, 2023

Health, Medical Devices, Health Technology, Other Health, Managed Care, General Health, Biotechnology, Obesity, Marriott Marquis, Washington Marriott Marquis, Conference, Nightclub, Broadcasting

Allurion, a company dedicated to ending obesity, today announced that it will be participating in the Jefferies Healthcare Conference taking place at the Marriott Marquis, New York, NY on June 7-9, 2023.

Key Points:

Allurion, a company dedicated to ending obesity, today announced that it will be participating in the Jefferies Healthcare Conference taking place at the Marriott Marquis, New York, NY on June 7-9, 2023.
Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Friday, June 9, 2023 at 9:30 A.M. Eastern Time, and will be available for investor 1x1 meetings.
A webcast of the event will be available on the Allurion website.

Blue Zones Project Petaluma Launches to Transform Community's Well-Being

Retrieved on:

Wednesday, May 31, 2023

PETALUMA, Calif., May 31, 2023 /PRNewswire/ -- Healthy Petaluma District and Foundation (Healthy Petaluma) and the City of Petaluma announce the launch of a city-wide Blue Zones Project to help residents live better, longer lives.

Key Points:

PETALUMA, Calif., May 31, 2023 /PRNewswire/ -- Healthy Petaluma District and Foundation (Healthy Petaluma) and the City of Petaluma announce the launch of a city-wide Blue Zones Project to help residents live better, longer lives.
Healthy Petaluma funded the initial Blue Zones Activate assessment, engaging the participation and collaboration of the City of Petaluma and over 100 community partners.
"We are thrilled to join forces with Healthy Petaluma to launch Blue Zones Project Petaluma," said Mayor Kevin McDonnell.
"After learning about the Blue Zones model years ago and speaking with other communities that have engaged Blue Zones, we pursued efforts to engage their team here in Petaluma, starting with a highly successful Blue Zones Assessment last year.

Global Market for Plant-Based Energy Drinks Expected to Reach $16 Billion by 2032

Retrieved on:

Wednesday, May 31, 2023

PALM BEACH, Fla., May 31, 2023 /PRNewswire/ -- The Energy drink market has been popular for the past several years but there is a new player on the block. Plant Based energy drinks. The demand for plant-based energy drinks is expected to be driven by a rise in people's understanding of fitness and an increasing number of health-conscious consumers. Consumers are started following different diets, such as vegan, and physical training, such as gyms, to improve their health. This change is mostly due to an increase in sedentary occupations and busy lifestyles. Also, the consumption of plant-based energy drinks improves the nutritional balance of the body. Plant-based energy drinks can help the immune system and combat diseases like obesity, diabetes, heart failure and cardiovascular disease. Consumers are increasingly concerned about their wellbeing and nutritional standards, so they are opting for energy drinks that are high in nutrients, vitamins, and low in sugar and fat, which is expected to grow the demand for plant-based energy drinks. A report from Future market Insights said that in 2022, the market for plant-based energy drinks was approximately worth $9 billion and that the Global market for plant-based energy drinks is expected to increase at a CAGR of 6.11% through 2032, reaching around US$ 16,285.7 Million by that year, driven by the expanding veganism trend. Active Companies from around the markets with current developments this week include: Yerbaé Brands Corp. (OTCPK: YERBF) (TSXV: YERB.U), Celsius Holdings, Inc. (NASDAQ: CELH), The Coca-Cola Company (NYSE: KO), PepsiCo, Inc. (NASDAQ: PEP), Monster Beverage Corporation (NASDAQ: MNST).

Key Points:

Plant-based energy drinks can help the immune system and combat diseases like obesity, diabetes, heart failure and cardiovascular disease.
A report from Future market Insights said that in 2022, the market for plant-based energy drinks was approximately worth $9 billion and that the Global market for plant-based energy drinks is expected to increase at a CAGR of 6.11% through 2032, reaching around US$ 16,285.7 Million by that year, driven by the expanding veganism trend.
Also, plants have become a more common source of protein, manufacturers have been urged to create protein-rich, healthier plant-based energy drinks, which is expected to propel the plant-based energy drink market forward.
The consumption of energy drinks has increased dramatically among the young generation, but the energy drinks currently available on the market contain caffeine, which has its own set of side effects, leading to an ongoing quest for caffeine substitutes and effective compounds to use in energy drinks."

Global Market for Plant-Based Energy Drinks Expected to Reach $16 Billion by 2032

Retrieved on:

Wednesday, May 31, 2023

PALM BEACH, Fla., May 31, 2023 /PRNewswire/ -- The Energy drink market has been popular for the past several years but there is a new player on the block. Plant Based energy drinks. The demand for plant-based energy drinks is expected to be driven by a rise in people's understanding of fitness and an increasing number of health-conscious consumers. Consumers are started following different diets, such as vegan, and physical training, such as gyms, to improve their health. This change is mostly due to an increase in sedentary occupations and busy lifestyles. Also, the consumption of plant-based energy drinks improves the nutritional balance of the body. Plant-based energy drinks can help the immune system and combat diseases like obesity, diabetes, heart failure and cardiovascular disease. Consumers are increasingly concerned about their wellbeing and nutritional standards, so they are opting for energy drinks that are high in nutrients, vitamins, and low in sugar and fat, which is expected to grow the demand for plant-based energy drinks. A report from Future market Insights said that in 2022, the market for plant-based energy drinks was approximately worth $9 billion and that the Global market for plant-based energy drinks is expected to increase at a CAGR of 6.11% through 2032, reaching around US$ 16,285.7 Million by that year, driven by the expanding veganism trend. Active Companies from around the markets with current developments this week include: Yerbaé Brands Corp. (OTCPK: YERBF) (TSXV: YERB.U), Celsius Holdings, Inc. (NASDAQ: CELH), The Coca-Cola Company (NYSE: KO), PepsiCo, Inc. (NASDAQ: PEP), Monster Beverage Corporation (NASDAQ: MNST).

Key Points:

Plant-based energy drinks can help the immune system and combat diseases like obesity, diabetes, heart failure and cardiovascular disease.
A report from Future market Insights said that in 2022, the market for plant-based energy drinks was approximately worth $9 billion and that the Global market for plant-based energy drinks is expected to increase at a CAGR of 6.11% through 2032, reaching around US$ 16,285.7 Million by that year, driven by the expanding veganism trend.
Also, plants have become a more common source of protein, manufacturers have been urged to create protein-rich, healthier plant-based energy drinks, which is expected to propel the plant-based energy drink market forward.
The consumption of energy drinks has increased dramatically among the young generation, but the energy drinks currently available on the market contain caffeine, which has its own set of side effects, leading to an ongoing quest for caffeine substitutes and effective compounds to use in energy drinks."

More than Half of Employees Delayed Necessary Medical Care due to Cost, 42% Delayed due to No Appointments Available, According to Integrated Benefits Institute Analysis

Retrieved on:

Friday, May 26, 2023

Insurance, Asthma, Obesity, Depression, Education, Diabetes, Culture, COVID-19, IBI, Mental, Patient, Immune system, Transport, Health, Integrated Benefits Institute, Mental health, Vaccine, Health insurance, Health care

OAKLAND, Calif., May 26, 2023 /PRNewswire/ -- At the height of the pandemic, individuals were asked to delay preventive care and elective procedures to alleviate incidences of community transmission. Many employers are now understandably concerned about the costs of delayed care, and the impact this has had on those with chronic conditions that may have gone untreated over the past three years. In an effort to understand who is delaying care and why they have delayed care, health and productivity research non-profit Integrated Benefits Institute surveyed 5,003 employed individuals in the US.

Key Points:

In an effort to understand who is delaying care and why they have delayed care, health and productivity research non-profit Integrated Benefits Institute surveyed 5,003 employed individuals in the US.
IBI's survey found that less than three-fourths of employees are up to date on preventive screenings and immunizations.
Fifty-eight percent of employees delayed necessary medical care due to cost or insurance barriers, 42% reported delays because there wasn't an appointment available, and 35% delayed or avoided care due to fear of getting or spreading COVID-19.
IBI spoke with two HR executives from large national and global companies about the effects of delayed care among their employees.

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

Retrieved on:

Thursday, May 25, 2023

Obesity, NASH, CML, McCormick Place, Cohort, Pharmacokinetics, Acute leukemia, ASCO, American Society of Clinical Oncology, Patient, Team Impulse, Annual general meeting, Fatty liver disease, Society, Safety, Pharmaceutical industry

FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that the TERN-701 (HS-10382) trial-in-progress (TiP) abstract is now available on the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting website. The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 2 - 6, 2023.

Key Points:

FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that the TERN-701 (HS-10382) trial-in-progress (TiP) abstract is now available on the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting website.
The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 2 - 6, 2023.
The TiP abstract details that patient enrollment reached Cohort 3 of the Dose Escalation phase as of February 2023, with seven participating study sites in China.
The TiP poster highlights completion of enrollment of Cohort 5 as of April 2023.

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

Retrieved on:

Thursday, May 25, 2023

Obesity, Therapy, GLP1, T2DM, GPCR, Patient, SAN, Overweight, Type, Pharmaceutical industry

SAN FRANCISCO and SHANGHAI, China, May 25, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus (T2DM) who are overweight or obese. The Company has also initiated an ethnobridging study of GSBR-1290 in Japanese individuals and is planning to initiate an additional formulation bridging study to evaluate a tablet formulation of GSBR-1290 before the end of the year, both in preparation for the planned global Phase 2b study in 2024.

Key Points:

The Company has also initiated an ethnobridging study of GSBR-1290 in Japanese individuals and is planning to initiate an additional formulation bridging study to evaluate a tablet formulation of GSBR-1290 before the end of the year, both in preparation for the planned global Phase 2b study in 2024.
“The initiation of the Phase 2a clinical trial marks a major milestone in our mission to bring an effective and convenient oral therapy to patients living with type 2 diabetes and obesity,” said Mark Bach, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics.
“We are excited to advance GSBR-1290, an orally available small molecule GLP1 agonist, into the next stage of clinical development.
This is the first program in our GLP-1 incretin franchise, and evaluating GSBR-1290 in Japanese patients demonstrates our commitment to rapidly developing this treatment globally.”